Results 141 to 150 of about 17,570 (253)

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. [PDF]

open access: yesArthritis Res Ther, 2021
Kay J   +17 more
europepmc   +1 more source

The 100 most-cited articles in COVID-19: a bibliometric analysis. [PDF]

open access: yesEur J Public Health
Liew YY, Dong Q, Lakshman N, Khajuria A.
europepmc   +1 more source

May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. [PDF]

open access: yesEur Heart J Suppl, 2020
Jankowski P   +19 more
europepmc   +1 more source

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. [PDF]

open access: yesRheumatology (Oxford), 2022
Furst DE   +18 more
europepmc   +1 more source

Outcomes of Voice Therapy in Behavioral Voice Disorders: A Scoping Review-Part A. [PDF]

open access: yesJ Voice
Ribeiro VV   +10 more
europepmc   +1 more source

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation. [PDF]

open access: yesPostepy Dermatol Alergol, 2020
Góralczyk A   +4 more
europepmc   +1 more source

Psychological Contract Breach and Outcomes: A Systematic Review of Reviews. [PDF]

open access: yesInt J Environ Res Public Health, 2022
Topa G, Aranda-Carmena M, De-Maria B.
europepmc   +1 more source

Home - About - Disclaimer - Privacy